Enhancing anti-tumor immunity through co-blocking PD-L1 and TIGIT by facilitating tumor-directed responses and additional VEGF inhibition

Combination therapy targeting the PD-1/PD-L1 and TIGIT pathways has been explored to enhance the efficacy of current immunotherapies. In this study, we investigated strategies to further potentiate the co-blockade of PD-L1 and TIGIT for cancer immunotherapy. Firstly, we demonstrated that the bispeci...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Xi Zhu, Xiaopei Cui, Haijia Yu, Jingen Xu, Xiaofang Chen, Xiaochen Ren, Xiaoyue Wei, Shi Chen, Yangtin Wang, Liyang Fei, Bin Xie, Mingwei Li, Xue Li, Huifeng Jia, Yujie Feng, Simin Xia, Li Chen, Yong Cheng, Lei Zhang, Haidong Li, Xiangyang Zhu, Yifan Zhan
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Frontiers Media S.A. 2026-01-01
Colecção:	Frontiers in Immunology
Assuntos:	bispecific antibody combination (combined) therapy PD-(L)1 TIGIT TME (tumor microenvironment) Treg - regulatory T cell
Acesso em linha:	https://www.frontiersin.org/articles/10.3389/fimmu.2025.1746155/full
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!